- Home
- ABVC vs SILO Comparison
ABVC vs SILO Comparison
Compare ABVC & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- SILO
- Stock Information
- Founded
- ABVC 2015
- SILO 2010
- Country
- ABVC United States
- SILO United States
- Employees
- ABVC N/A
- SILO N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- ABVC Health Care
- SILO Consumer Discretionary
- Exchange
- ABVC Nasdaq
- SILO Nasdaq
- Market Cap
- ABVC 52.1M
- SILO 5.9M
- IPO Year
- ABVC N/A
- SILO N/A
- Fundamental
- Price
- ABVC $2.86
- SILO $0.70
- Analyst Decision
- ABVC
- SILO
- Analyst Count
- ABVC 0
- SILO 0
- Target Price
- ABVC N/A
- SILO N/A
- AVG Volume (30 Days)
- ABVC 82.7K
- SILO 941.5K
- Earning Date
- ABVC 11-13-2025
- SILO 11-11-2025
- Dividend Yield
- ABVC N/A
- SILO N/A
- EPS Growth
- ABVC N/A
- SILO N/A
- EPS
- ABVC N/A
- SILO N/A
- Revenue
- ABVC $391,242.00
- SILO $72,102.00
- Revenue This Year
- ABVC $735.18
- SILO $1.86
- Revenue Next Year
- ABVC N/A
- SILO N/A
- P/E Ratio
- ABVC N/A
- SILO N/A
- Revenue Growth
- ABVC 186.84
- SILO N/A
- 52 Week Low
- ABVC $0.40
- SILO $0.41
- 52 Week High
- ABVC $5.48
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- ABVC 49.97
- SILO 54.08
- Support Level
- ABVC $2.64
- SILO $0.58
- Resistance Level
- ABVC $2.90
- SILO $0.83
- Average True Range (ATR)
- ABVC 0.16
- SILO 0.05
- MACD
- ABVC 0.01
- SILO 0.01
- Stochastic Oscillator
- ABVC 55.64
- SILO 48.39
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.